BioSpace News Archive

These PoC results in animal models represent a significant advancement in Mindset’s development of its new psychedelic drug program.

Technology and consulting firm, Headspring, received FDA approval of their first product built for the Plasma industry. Developed in partnership with the Protein Plasma Therapeutics Association (PPTA), this new National Donor Deferral Registry & Cross Donation Check System (NDDR & CDCS) protects both patients, donors and collectors

Xenex Disinfection Services Inc., a world leader in UV technology-based disinfection strategies and solutions, announced the launch of Deactivate™, a high-powered, handheld LED device designed to quickly disinfect surfaces in confined spaces.

Elevate Dynamics Announces Exclusive U.S. Agreement with SPS to Distribute its AFO1 TM Product Line SPS will be the exclusive U.S. distributor of Elevate Dynamics’ AFO product line.

Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (LSE:RENX / NASDAQ: RNLX), and manufacturing partner Bio-Techne Corporation (NASDAQ: TECH), announced that the U.S. Food and Drug Administration (FDA) has added COVID-SeroKlir to the Emergency Use Authorization (EUA

Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced private offer to exchange (the “Exchange Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Old Notes”), totaling $1.75 billion in aggregate principal amount, for a new series of 3.250% senior notes due 2051 to be issued by Biogen

Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will participate in an upcoming investor conference. On Thursday, February 25, at 2:20 p.m. ET, Fred P. Lampropoulos, President and Chief Executive Officer

Hoth Therapeutics today announced that Scientific Advisory Board member, Michael Peter, Ph.D., published a whitepaper in bioRxiv regarding COVID-19 SARS-CoV-2 titled, “Transformations, Comparisons, Analysis of Down to Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein including the UK Variant B.I.I.7.”

Fluidigm Corporation, an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced financial results for the fourth quarter and full year ended December 31, 2020.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the fourth quarter and year-end 2020, after the market close on Wednesday, February 17, 2021.